Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alzamend NeuroALZN +1.18%21 EV-to-OCF is -0.94 as of Sep. 11, 2026. GuruFocus rates ALZN with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 1,405 Biotechnology companies, Alzamend Neuro ranks worse than 64.98% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Alzamend Neuro's Enterprise Value is $7.59 Mil.
Alzamend Neuro's Cash Flow from Operations for the trailing twelve months (TTM) ended in Apr. 2026 was $-8.07 Mil. Therefore, Alzamend Neuro's EV-to-OCF for today is -0.94.
The historical rank and industry rank for Alzamend Neuro's EV-to-OCF or its related term are showing as below:
ALZN'
s EV-to-OCF Range Over the Past 10 Years
Min: -0.96 Med: 0 Max: -0.89
Current: -0.94
During the past 8 years, the highest EV-to-OCF of Alzamend Neuro was -0.89. The lowest was -0.96. And the median was .
ALZN's EV-to-OCF is ranked worse than 64.98% of 1405
companies
in the Biotechnology industry
Industry Median: -3.4
vs ALZN: -0.94
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alzamend Neuro's PE Ratio (TTM) for today is calculated as:
Alzamend Neuro's share price for today is $1.72.
Alzamend Neuro's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.900.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Alzamend Neuro EV-to-OCF Related Terms
Alzamend Neuro EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Alzamend Neuro's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alzamend Neuro's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alzamend Neuro EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alzamend Neuro's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Alzamend Neuro's EV-to-OCF falls into.
Alzamend Neuro's current Enterprise Value is $7.59 Mil.
Alzamend Neuro's Cash Flow from Operations for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alzamend Neuro (ALZN) has a EV-to-OCF of -0.94 as of Sep. 11, 2026. According to the industry distribution chart, Alzamend Neuro ranks #913 out of 1405 companies in the Biotechnology industry, placing it in the top 65%.
Is Alzamend Neuro's EV-to-OCF too high?
Alzamend Neuro's current EV-to-OCF is -0.94. Based on the distribution chart, Alzamend Neuro ranks #913 out of 1405 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alzamend Neuro has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Alzamend Neuro's EV-to-OCF compare to CNSP and SNGX?
According to the Biotechnology industry distribution chart, Alzamend Neuro ranks #913 out of 1405 companies for EV-to-OCF. This places Alzamend Neuro in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Alzamend Neuro's current EV-to-OCF is -0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzamend Neuro stock overvalued right now?
Alzamend Neuro (ALZN) has a current EV-to-OCF of -0.94. The current EV-to-OCF is -0.94. Alzamend Neuro's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Alzamend Neuro (ALZN), the current EV-to-OCF is -0.94 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
21GF Score
Get the complete analysis for ALZN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALZN has been successfully added to your 
